Related Experiment Video

Updated: Jul 8, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Boron neutron capture therapy for glioblastoma: is it worth pursuing?

Ute Linz1

  • 1Forschungszentrum Julich GmbH, D-52425 Julich, Germany. u.linz@fz-juelich.de

Technology in Cancer Research & Treatment
|January 18, 2008
PubMed

Insights

Boron neutron capture therapy (BNCT) is unlikely to effectively treat glioblastomas, an incurable brain tumor. A 50-year review suggests BNCT should remain experimental, not advanced for clinical use.

Area of Science:

  • Oncology
  • Radiotherapy
  • Medical Physics

Background:

  • Glioblastomas are aggressive, currently incurable brain tumors.
  • Boron neutron capture therapy (BNCT) is being investigated as a potential treatment.
  • Significant research efforts worldwide are focused on BNCT for glioblastomas.

Purpose of the Study:

  • To evaluate the probable efficacy of Boron Neutron Capture Therapy (BNCT) for treating glioblastomas.
  • To critically assess the scientific basis for advancing BNCT beyond its experimental phase for this specific cancer.

Main Methods:

  • Pharmacological analysis of BNCT agents.
  • Cell biological evaluation of BNCT mechanisms in tumor cells.
  • Comprehensive review of published literature on BNCT for glioblastomas over the past 50 years.

Main Results:

  • Pharmacological and cell biological factors suggest BNCT is unlikely to be effective against glioblastomas.
  • A 50-year literature review provides no evidence to support the development of BNCT for glioblastomas.

Conclusions:

  • Current evidence indicates Boron Neutron Capture Therapy (BNCT) is not a viable treatment for glioblastomas.
  • Further development of BNCT for glioblastomas is not scientifically justified at this time.

More Related Videos

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...